Acer Therapeutics Inc

Antagen Pharmaceuticals Inc., based in Canton, Massachusetts, is a pioneering biotechnological company committed to developing innovative solutions for pressing healthcare challenges, including infectious diseases, cancer, and autoimmune disorders. With a mission focused on revolutionizing healthcare through advanced research and technology platforms, Antagen is at the forefront of delivering cutting-edge biomedical services and products. Offering a comprehensive array of biotechnological services, Antagen specializes in therapeutic antibody development, recombinant protein production, and the development of COVID-19 detection kits. Their dedication to quality and innovation has garnered positive testimonials from clients who praise the company's expertise and reliability in the industry. Generated from the website

Paratek Pharmaceuticals, based in Boston, MA, is a biopharmaceutical company dedicated to addressing the critical global public health issue of antimicrobial resistance (AMR). With a focus on developing innovative treatment options for complex medical issues, Paratek is committed to combatting AMR through responsible antibiotic use, improved surveillance, and research into new antibiotics. Grounded in a mission to save lives, Paratek's FDA-approved tetracycline-class antibiotic, NUZYRA, targets adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. The company's disciplined team of experts is driven to provide new technologies that can defeat superbugs and contribute to a vibrant marketplace that recognizes the life-saving value of novel antibiotics.Generated from the website

Syntonix Pharmaceuticals is engaged in the discovery and development of novel, long-acting, proprietary therapeutic products that utilize the company s proprietary Fc-fusion proteins and other engineered ligands that bind to specific Fc receptors. These technologies, including the Transceptor drug-delivery platform, are designed to use the body s natural protection of antibodies against premature destruction and for the transport of antibodies across cell barriers. The company focuses on using these technologies to create next-generation treatments for chronic diseases such as hemophilia, anemia and autoimmune disorders. It develops selected products for specialty indications and evaluates and commercializes other products through partnerships. The company occupies a 25,000-square-foot laboratory facility that includes a clinical manufacturing suite. Syntonix Pharmaceuticals is headquartered in Waltham, Mass.